Polyrizon (PLRZ) Common Equity (2023 - 2025)
Polyrizon's (PLRZ) quarterly Common Equity came in at $21.0 million in Q4 2025, up 297.16% YoY from $5.3 million in Q4 2024, and up 14.25% on a QoQ basis from $18.4 million in Q2 2025.
Polyrizon (PLRZ) Common Equity (2023 - 2025) Analysis & Trends
Polyrizon (PLRZ) has 3 years of Common Equity data on file, last reported at $21.0 million in Q4 2025.
- Quarterly Common Equity rose 297.16% year-over-year to $21.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.0 million (up 297.16% YoY) and the FY2025 annual result came in at $21.0 million, up 297.16% from the prior year.
- Common Equity improved to $21.0 million in Q4 2025, from $18.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $21.0 million in Q4 2025 to a low of -$191000.0 in Q4 2023.
- A 3-year average of $11.1 million and a median of $11.8 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity soared 2867.54% — and 2025, when it jumped 297.16%.
- Tracing PLRZ's Common Equity over 3 years: stood at -$191000.0 in 2023, then soared by 2867.54% to $5.3 million in 2024, then jumped by 297.16% to $21.0 million in 2025.
- The last three Common Equity figures came in at $21.0 million (Q4 2025), $18.4 million (Q2 2025), and $5.3 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Polyrizon | 7.27 Mn | -4.22 Mn | - | 20.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.99 Mn |
| Jun 30, 2025 | 18.38 Mn |
| Dec 31, 2024 | 5.29 Mn |
| Dec 31, 2023 | -191,000.00 |